Safer Dividend King to Buy Now: AbbVie or Johnson & Johnson?

There are plenty of dividend stocks on equity markets. Few are more secure than Dividend Kings, a group of corporations that have raised their payouts annually for at least 50 years straight. This is a highly exclusive clique that features only a few dozen companies, including Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV), two leading pharmaceutical giants. Both drugmakers clearly have reliable dividend programs, but which one is safer to invest in right now? Let's find out. Image source: The Motley Fool.Johnson & Johnson is one of the more diversified healthcare stocks on the market. The company's business spans pharmaceuticals and medical devices. Within both niches, Johnson & Johnson operates across many different areas, including oncology and neuroscience in its drugmaking business, and surgery and vision care within medtech, among others. Johnson & Johnson's large product portfolio has enabled it to navigate stiff competition and patent cliffs. Despite losing U.S. patent exclusivity for Stelara, a notable growth driver, last year, the company's revenue increased.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool